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In mass spectrometry- (MS-) based quantitative proteomics research, the
emerging iTRAQ (isobaric tag for relative and absolute quantitation) tech-
nique has been widely adopted for high throughput protein profiling. In a
typical iTRAQ proteomics study, samples are grouped into batches and each
batch is processed by one iTRAQ multiplex experiment, in which the abun-
dances of thousands of proteins/peptides in a batch of samples can be mea-
sured simultaneously. The iTRAQ technique greatly enhances the throughput
of protein quantification. However, the technical variation across different
iTRAQ multiplex experiments is often large due to the dynamic nature of MS
instruments. This leads to strong batch effects in the iTRAQ data. Moreover,
the iTRAQ data often contain substantial batch-level non-ignorable missing-
ness. Specifically, the abundance measures of a given protein/peptide are of-
ten either observed or missing altogether in all the samples from the same
batch, with the missing probability depending on the combined batch-level
abundances. We term this unique missing-data mechanism as the Batch-level
Abundance-Dependent Missing-data mechanism (BADMM). We introduce
a new method — mixEMM — for analyzing iTRAQ data with batch effects
and batch-level non-ignorable missingness. The mixEMM method employs a
linear mixed-effects model and explicitly models the batch effects and the
BADMM in the likelihood function. With simulation studies, we showed that
compared with existing approaches that utilize relative abundances and ig-
nore the missing batches under the missing-completely-at-random assump-
tion, the mixEMM method achieves more accurate parameter estimation and
inference. We applied the method to an iTRAQ proteomics data from a breast
cancer study and identified phosphopeptides differentially expressed between
different breast cancer subtypes. The method can be applied to general clus-
tered data with cluster-level non-ignorable missing-data mechanisms.
1. Introduction.
1.1. Quantitative proteomics research and the iTRAQ technique. Proteins are
complex macromolecules responsible for nearly every task of cellular life and es-
sential for the structure, function, and regulation of human tissues and organs.
Nonetheless, the discovery of protein biomarkers in cancer diagnosis, prevention
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and treatment has only achieved modest successes, partially because that the abun-
dances of proteins are difficult to be quantified. To date, MS-based platforms still
serve as the workhorses in quantitative proteomics research. Traditional shotgun
MS experiments usually process samples one by one; and the process of each sam-
ple involves extensive fractionation, resulting in weeks of MS time. The huge time
and cost required for such experiments greatly limit the scale of most proteomics
studies.
To improve the efficiency of MS-based protein quantification, the iTRAQ (iso-
baric Tag for relative and Absolute Quantitation) technique was introduced about
a decade ago (Ross et al., 2004; Wiese et al., 2007). It enables multiplexing (com-
paring) of up to 4 or 8 different samples in one MS-based experiment with 4 or
8 “channels” (i.e. 4-plex or 8-plex reagents). Specifically, in an iTRAQ-MS based
study, samples are firstly grouped into batches (4 or 8 samples per batch), and
then each batch is processed by one iTRAQ multiplex experiment following three
steps: (1) intact proteins of each sample are enzymatically digested into smaller
segments of amino acid sequences, i.e. peptides; (2) peptides from different sam-
ples in one batch are labelled with different isotope-coded covalent tags and are
mixed together; (3) the mixtures are introduced into MS instruments, where pep-
tides from different samples in the batch are identified and quantified together.
In this way, multiple samples can be processed together and that greatly reduces
the overall quantification time and cost. Moreover, iTRAQ labeling was reported
to be superior to other competing platforms in quantitative proteomics research
(Mertins et al., 2012). In 2014 alone, there are more than 2,000 publications in-
volving iTRAQ experiments according to the Google Scholar. Apparently, the en-
hancement of throughput with iTRAQ had greatly advanced proteomics research.
1.2. A motivating iTRAQ proteomics data from the CPTAC project. In order
to improve our ability to diagnose, treat and prevent cancer, the National Cancer
Institute launched the Clinical Proteomic Tumor Analysis Consortium (CPTAC,
http://proteomics.cancer.gov) to systematically identify proteins that are derived
from alterations in cancer genomes (Paulovich et al., 2010; Ellis et al., 2013). The
CPTAC has recently conducted global proteome and phosphoproteome profiling
of a subset of breast, colon and ovarian cancer samples that have been extensively
characterized in The Cancer Genome Atlas (TCGA , http://cancergenome.nih.gov)
(The Cancer Genome Atlas Network, 2012). This is so far the first attempt to char-
acterize protein activities in cancer samples using sophisticated proteomics exper-
iments on a large scale. For example, in the breast cancer project, a total of 108
breast cancer tumor samples were analyzed with iTRAQ experiments, with the goal
of identifying proteins related to breast cancer clinical variables and outcomes.
Anther aim of the CPTAC project is to “set standards, establish procedures, and
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provide reagents to enable cancer researchers to effectively and reproducibly use
proteomics approaches” (Paulovich et al., 2010; Ellis et al., 2013). Advances in
methods and tools, especially the ones accounting for the unique characteristics
of iTRAQ data, such as the method proposed in this paper, will better facilitate
the achievement of those missions, and will in turn lead to improved diagnostics,
therapies, and potentially preventive measures for cancer.
In this paper, we will focus on analyzing the phospho-proteomics data from
the breast cancer CPTAC study. Phosphorylation is a key post-translational modi-
fication and plays a central role in many biological processes. Phosphorylation at
different sites of one protein could induce different biological activities. Our goal is
to identify individual phosphorylated peptides, i.e., phosphopeptide, up or down-
regulated in triple negative breast cancer tumors compared to other subtypes of
breast cancer. The investigation will provide important insights into breast cancer
etiology and help to identify protein biomarkers.
1.3. Batch effect and batch-level non-ignorable missing data. Given the pop-
ularity and the efficiency of the iTRAQ technique, there is a pressing need for
tailored methods development for iTRAQ data. Though the iTRAQ-based batch-
processing greatly reduces the cost and improves the efficiency of data genera-
tion, the consequent batch-effects are substantial due to the dynamic nature of MS
instrument. To alleviate this problem, a general practice is to include a common
reference sample in each batch for quality control. For example, in the 4-plex
iTRAQ experiments of the CPTAC breast cancer study, each batch consisted of
3 breast tumor samples and a (same) reference sample. The reference sample was
created by combining 40 tumor samples in the CPTAC breast cancer study. Con-
ventional data analyses are usually performed based on the relative abundances of
proteins/peptides in the target samples relative to the reference sample in the same
batch (Mertins et al., 2012; Karp et al., 2010). This strategy helps to account for the
variation across different iTRAQ multiplex experiments to a certain extent. How-
ever, due to the complicated process of protein/peptide identification and quantifi-
cation in the MS instruments, there is a large variation among the measurements
of the reference sample across different experiments/batches, and the target sam-
ples and the reference sample could be subjected to different variances (Karp et al.,
2010). The relative abundance measures can not fully capture these data features.
Another unique challenge in the iTRAQ data analysis is the substantial amount
of batch-level non-ignorable missing data. It is well known that in the general MS
experiments, the lower the abundance of a given peptide is, the more likely the
peptide is missing in the output data (Wang et al., 2006; Chen, Prentice and Wang,
2014). With iTRAQ-MS experiments, since all of the samples in a batch are pro-
cessed together, a given peptide is either detected and quantified or missing si-
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multaneously in the samples from the same batch. The missing data probability
of the peptide largely depends on the combined abundances of the peptide from
all of the batch samples in the experiment (the batch-level abundance). We term
this missing-data mechanism in the iTRAQ proteomics data as the “Batch-level
Abundance-Dependent Missing-data mechanism (BADMM)”. Figure 1 shows an
illustration of the iTRAQ data on one peptide and its BADMM. Subsequently, pro-
tein quantification is often obtained as a summary of the peptide abundances in the
protein and is also subject to the BADMM. In addition to BADMM, there may be
sporadic missingness created at the individual sample level. Here sporadic miss-
ingness refers to the scenario where a peptide/protein is missing in some but not
all of the samples from the same batch. Since the proportion of sporadic missing
data is usually small (e.g. < 1% sporadic versus > 99% batch-level missingness
in the motivating CPTAC data set), we assume these sporadic missing-values are
missing-completely-at-random and are ignorable (Rubin, 1976).
 
Experiment
/Batch 
Reference 
Channel 
Channel 1 Channel 2 Channel 3 
Experiment  
random-effects 
Missing 
Indicator 
1 1RY  11Y  12Y  13Y  1b  1 0M   
2 2RY  21Y  22Y  23Y  2b  2 1M   
      
i iRY  1iY  2iY  3iY  ib  0iM   
      
Q QRY  1QY  2QY  3QY  Qb  0QM   
 
 
Fig 1: An illustration of a 4-plex iTRAQ data for one peptide. There are often tens
of thousands of peptides being quantified simultaneously. Let YQ×4 be the abun-
dance data for the peptide. A total of 3 ×Q tumor samples are randomly grouped
into Q batches and are processed by Q iTRAQ experiments. In each iTRAQ ex-
periment i (i = 1, . . . , Q), the three tumor samples are placed on three channels,
and a reference sample is also placed on one channel for quality control purposes.
The samples in the same batch are processed together, and often will be observed
or missing together. If missing, the missing indicator for the i-th batch, Mi is set
to be 1. The missing probability of the batch relates to the total peptide abundance
level in the batch. The lower the total abundance, the more likely the peptide will
be missing in the experiment (batch).
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Given the presence of severe batch effects, substantial batch level missingness
(∼ 40% in our motivating CPTAC data), and small sample sizes in most iTRAQ
proteomics data, it is very essential to account for the batch design and the non-
ignorable missingess in a deliberate way to improve the precision of estimation and
inference with iTRAQ data. In this work, we propose to directly model the absolute
abundances of proteins/peptides and their variance structures considering the batch
design. By modeling the absolute abundances instead of the relative abundances,
we can better characterize the variance of protein abundances in target samples, and
improve the power of statistical tests. This strategy has been employed for analyz-
ing other types of proteomics data from targeted mass spectrometry experiments
(Chang et al., 2012). Since samples in the same batch are subject to the same ex-
perimental conditions and procedures, a mixed-effects model with a random effect
for each batch is a natural way to account for the experimental design (Laird and
Ware, 1982).
The BADMM in the iTRAQ data hinders the direct application of a mixed-
effects model. With BADMM, the probability of a protein/peptide being missing
in a batch depends on the combined abundance of the protein/peptide in the batch.
The missing data are not-missing-at-random and are non-ignorable (Rubin, 1976).
In order to obtain unbiased estimation and valid inference, the missing-data mech-
anism needs to be properly modelled and accounted for. Existing work on mod-
elling the non-ignorable missingness in iTRAQ data (Hill et al., 2008; Luo et al.,
2009; Oberg et al., 2008) and the selection model for longitudinal data with non-
ignorable missingness (Ibrahim, 1990) consider the probability of missingness for
a protein/peptide in each sample independently. If a protein/peptide is missing in
the entire batch, the values in the batch will be ignored by existing methods, leading
to biased estimation and unfaithful inference. In contrast, we propose to model the
batch-level missing-data pattern (BADMM) and incorporate it in a mixed-effects
model: we model the probability of a protein/peptide being missing (in all of the
samples) in a batch as a function of the total protein/peptide abundances in the cur-
rent batch. This probabilistic missing-data mechanism provides an attractive way
to account for the characteristics of iTRAQ and MS experimental complexities.
Compared to a censoring model (Little and Rubin, 2002), it does not depend on a
fixed detection threshold and is more flexible, and it better depicts the experimental
procedure.
1.4. Outline. To properly analyze iTRAQ data, as characterized by the data
from the CPTAC project, we introduce mixEMM — a mixed-effects model cou-
pled with the probabilistic BADMM in Section 2. In Section 3, we use an Expec-
tation and Conditional Maximization (ECM) algorithm to estimate the fixed and
random effects in mixEMM. We also present an alternative probability function for
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BADMM that may be suitable for more general settings. In Section 4, we perform
simulations to evaluate the performance of the mixEMM method. In Section 5, we
apply the proposed method to the motivating CPTAC iTRAQ data and identify
phosphopeptides related to breast cancer subtypes. In Section 6, we summarize the
work as a useful tool for analyzing iTRAQ proteomics data, and moreover, as a
general framework to handle cluster-level non-ignorable missing-data patterns for
data with repeated or clustered measures.
2. Amixed-effects model with batch-level non-ignorable missingness. Con-
sidering one feature (e.g., a phosphopeptide) of interest, let Y = {yi}Qi=1 denote
the underlying complete (observed and missing) abundances for this feature in all
of the samples in the Q batches (Q = 36 in the motivating CPTAC breast can-
cer dataset). Specifically, yi is a pi × 1 data vector, where pi is the number of
samples in the ith batch. Suppose this feature is only observed in Qobs batches
(Qobs ≤ Q). Let yobs and ymis denote the observed and missing data, respectively,
and Y = {yobs,ymis}.
Samples in the same batch are processed by one iTRAQ multiplex experiment,
and are subject to the same experimental procedure and are correlated. We use a
linear mixed-effects model to account for such correlations:
(1) yi = Xiα+ Zibi + ei,
where Xi is a known fixed design matrix with dimension pi×k;α is a k×1 vector
of parameters for fixed effects; Zi is a known covariate matrix for random effects
with dimension pi × h; bi ∼ N(0,Dh×h) represents the random effect coefficient
specific to each batch of samples; and ei
i.i.d.∼ N(0,Ri) has diagonal covariance
matrix of dimension pi × pi. In our data application, Xi consists of a column of
1’s, an indicator variable for the reference sample, and a set of clinical variables
(for example, cancer subtype indicators); random effect bi is of length 1 (h = 1);
Zi is a vector of 1’s; and for 4-plex iTRAQ experiments, Ri has diagonal elements
{σ20, σ2, σ2, σ2} , where σ20 is the variance corresponding to the reference sample
and σ2 is the variance of the other three samples. Since the reference sample was
created by combining 40 tumor samples in the CPTAC breast cancer study, we
expect it to have a different variance than other individual tumor samples.
According to (1), we have yi ∼ N(Xiα,Σi), where Σi = ZiDZTi + Ri.
Our goals are to obtain the maximum likelihood estimates (MLEs) of the fixed
and random effects while accounting for the non-ignorable BADMM and to draw
inferences on the fixed effects for identifying features related to clinical variables
(Xi).
As described in the previous section, for a given feature, the lower its combined
abundance across all of the samples in one batch, the more likely all measures of the
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feature in the batch will be missing during the experiment. Let Mi be the missing
indicator of this feature in the ith batch, and Mi = 1 if the ith batch is missing,
otherwise Mi = 0. We model this BADMM using an exponential probabilistic
model:
(2) Pr(Mi = 1|yi) = g(1Tyi; γ0, γ) = exp(−γ0 − γ/pi · 1Tyi),
where γ0 and γ are non negative parameters. Since yi are abundance measures and
are all positive, yi > 0, the above probability function always takes value between
0 and 1.
We first treat γ0 and γ as known missing-data mechanism parameters. We dis-
cuss extensions to cases where those parameters are unknown in Section 3.3. More-
over, in Section 3.5, we discuss other flexible probability functions for BADMM.
Our goal is to obtain the MLEs that maximize the observed-data likelihood func-
tion considering the missing-data mechanism:
Ωˆ = argmax
Ω
L(yobs,M;Ω)
where Ω = {α, σ20, σ2,D} denotes the set of parameters of interest. Directly solv-
ing the above likelihood function for MLEs is difficult. Therefore, we propose to
employ an ECM algorithm, and we term the proposed method as mixEMM (Mixed-
Effects Models with BADMM).
3. An ECM algorithm to calculate MLEs. If ymis and bi were observed, the
MLEs for Ri, D andα based on the likelihood of the complete data (yobs,ymis, b,M)
can be easily calculated. Thus, we employ an ECM algorithm (Meng and Rubin,
1993): in the expectation (E) step of the (t+1)-th iteration, we calculateQ(Ω|Ω(t))
— the expected value of the log-likelihood given the observed data and current pa-
rameter estimates. In the conditional maximization (CM) step, we obtain the cur-
rent parameter estimates Ωˆ(t+1) by maximizing Q(Ω|Ω(t)). Given the proposed
BADMM in equation (2), closed form solutions are available in the CM step. By
iterating through the E and CM steps, the likelihood of the observed data will al-
ways increase, and we obtain the MLEs at the convergence (Chen, Prentice and
Wang, 2014).
3.1. E step. In the E step, the expected log likelihood function for the complete
data given the observed data and the current parameter estimates is given by
Q(Ω|Ω(t)) = Eymis,b|yobs,M;Ω(t) [logL(Ω;yobs,ymis, b,M)] .
=
∑
i∈O
Ebi|yi,Mi;Ω(t)`(yi, bi,Mi = 0;Ω) +
∑
i/∈O
Eyi,bi|Mi;Ω(t)`(yi, bi,Mi = 1;Ω)
= I1 + I2,
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where O denotes the set of indices of the observed batches. Existing literature on
modelling the non-ignorable missingness in iTRAQ data (Hill et al., 2008; Luo
et al., 2009; Oberg et al., 2008) and the selection model for longitudinal data with
non-ignorable missingness (Ibrahim, 1990) consider the probability of missingness
of a feature in each sample independently. Those methods can handle sample-level
non-ignorable missing data, but are not directly applicable to iTRAQ data with
batch-level missingness. In contrast, we will take the missing batches into account
by explicitly modeling the BADMM – a major innovation of the proposed method.
For the observed batches,
I1 =
∑
i∈O
Ebi|yi,Mi;Ω(t) {log [f(yi|α,Ri, bi)] + log [f(bi|D)] + log [f(Mi = 0|yi)]} .
The last term log [f(Mi = 0|yi)] does not involve parameters of interest.
To obtain the conditional expectation, we first calculate the conditional distribu-
tion of bi for i ∈ O as a normal distribution with mean and variance
b
(t)
i = E(bi|yi,Mi = 0,Ω(t)) = D(t)ZTi W(t)i (yi −Xiα(t)),(3)
∆
(t)
i = var(bi|yi,Mi = 0,Ω(t)) = D(t) −D(t)ZTi W(t)i ZiD(t),(4)
where W(t)i = (Σ
(t)
i )
−1 = (ZiD(t)ZTi + R
(t)
i )
−1. It follows that
I1 = const− 1/2
∑
i∈O
(
log |Ri|+ (yi −Xiα− Zib(t)i )
T
R−1i (yi −Xiα− Zib(t)i )
+tr(V(t)i R
−1
i ) + log |D|+ b(t)i
T
D−1b(t)i + tr(D
−1∆(t)i )
)
,
where V(t)i = var(ei|yi,Mi = 0,Ω(t)) = Zi∆(t)Zi for i ∈ O.
To calculate I2, we first compute the conditional expectation and variance of yi
and bi for i /∈ O. Given Pr(Mi = 1|yi) in equation (2), it is easy to see that, for
i /∈ O,
y
(t)
i = E(yi|Mi = 1,Ω(t)) = Xiα(t) − γ/piΣ(t)i 1,(5)
var(yi|Mi = 1,Ω(t)) = Σ(t)i ,(6)
where Σ(t)i = ZiD
(t)ZTi + R
(t)
i . It follows that, for i /∈ O,
b
(t)
i = E(bi|Mi = 1,Ω(t)) = E(E(bi|yi,Ω(t))|Mi = 1,Ω(t))(7)
= D(t)ZTi W
(t)
i (y
(t)
i −Xiα(t)),
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∆
(t)
i = var(bi|Mi = 1,Ω(t))(8)
= E(var(bi|yi,Ω(t))|Mi = 1,Ω(t)) + var(E(bi|yi,Ω(t))|Mi = 1,Ω(t))
= D(t),
V
(t)
i = var(ei|Mi = 1,Ω(t)) = R(t)i .(9)
Then we can obtain the following for the missing batches of samples
I2 =
∑
i/∈O
Eyi,bi|Mi;Ω(t) {log [f(yi|α,Ri, bi,Mi = 1)] + log [f(bi|D)] + log [f(Mi = 1|yi)]}
= const− 1/2
∑
i/∈O
(
log |Ri|+ (y(t)i −Xiα− Zib(t)i )
T
R−1i (y
(t)
i −Xiα− Zib(t)i ) + tr(V(t)i R−1i )
+ log |D|+ b(t)i
T
D−1b(t)i + tr(D
(−1)D(t)) + 2γ/pi · 1Ty(t)i
)
.
3.2. CM step. In the CM step, we sequentially maximize the expected complete-
data log likelihood for the parameters of interest. In the first step of CM, we obtain
the estimate for D that maximizes Q(Ω|Ω(t)):
D(t+1) =
1
Q
Q∑
i=1
(
b
(t)
i b
(t)
i
T
+ ∆
(t)
i
)
.(10)
Then conditioned on the current R(t)i , the maximum estimate for α is given by
α(t+1) =
(
Q∑
i=1
XTi (R
(t)
i )
−1
Xi
)−1( Q∑
i=1
XTi (R
(t)
i )
−1
(y
(t)
i − Zib(t)i )
)
,(11)
where y(t)i = yi when Mi = 0, and y
(t)
i = Xiα
(t) − γ/piΣ(t)i 1 when Mi = 1.
Lastly, we can obtain the estimates for σ2(t+1)0 and σ
2(t+1) conditioned onα(t+1):
σ0
2(t+1) =
1
Q
Q∑
i=1
[(
y
(t)
i1 −Xi1α(t+1) − Zi1b(t)i
)2
+ v
(t)
i11
]
, and(12)
σ2(t+1) =

Q∑
i=1
 pi∑
j=2
(
y
(t)
ij −Xijα(t+1) − Zijb(t)i
)2
(13)
+
(
tr V(t)i − v(t)i11
)]}
/(
Q∑
i=1
pi −Q),
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where v(t)i11 denotes the first diagonal element of V
(t)
i . By iterating through the
E- and CM- steps, MLEs for the fixed effects and variance components can be
obtained.
In addition, through computing the information matrix of the log-likelihood
function of the observed data, we can estimate the variance of αˆ using
v̂ar(αˆ) =
(∑
i∈O
XiWiXi
)−1
.(14)
We can then perform test for α by rejecting H0 : αi = 0 for large value of
αˆi/ŝdαˆi .
3.3. Estimation of the missing-data mechanism parameter. In real applica-
tions, the missing-data mechanism parameter Γ = {γ0, γ} in (2) is often unknown
and needs to be estimated. One simple approach is to use the missing percentage
and mean abundance based on available data of each feature to model the rela-
tionship between the probability of missingness and the abundance. Specifically,
we assume all of the features in one data set are subject to the same missing-data
mechanism. We calculate the average abundance for each feature j based on the
observed data and denote it as tj , and we also obtain the missing percentage of
feature j as pij = 1 − Qj,obs/Q, where Qj,obs is the number of batches in which
feature j is quantified. We can estimate Γ in (2) by
Γˆ = argmin
Γ={γ0,γ}
∑
j
(log(pij) + γ0 + γtj)
2 .(15)
Alternatively, one can also employ a profile likelihood approach proposed in
Chen, Prentice and Wang (2014) to jointly estimate the parameters of interest and
the missing-data mechanism parameters. LetLΓ(Ω) = L(yobs,M;Ω,Γ).One can
evaluate LΓ(Ω) at different Γ values and choose the Γ that gives the maximum
over the likelihood profile. As shown in Chen, Prentice and Wang (2014) with
both simulations and real data examples, the estimated Γ based on available-case
estimates of protein abundance is very close to the profile-likelihood estimates,
especially when the sample size is limited as in most proteomics studies. Moreover,
in Section 5.3, we demonstrate that the available-case estimate of Γ is very close to
the true values under all the simulation settings considered in this paper. Thus, we
use the available-case estimates of the missing-data mechanism parameter in our
data analysis.
3.4. An outline of the algorithm to fit the mixEMM model. In summary, we
implement an ECM algorithm to fit the mixEMM model for analyzing iTRAQ pro-
teomics data. An outline of the ECM algorithm is provided in Algorithm 1. Note, for
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Algorithm 1 An algorithm to fit the mixEMM model.
1. Estimate missing-data mechanism parameter Γ by (15).
2. Obtain the initial estimate Ω(0) for fixed effects and variance components.
3. E-step: For the exponential missing-data mechanism function, given Γˆ, calculate the conditional
expectations and variances of ymis, ei, bi given the observed yobs, M and the current parameter
estimates Ωˆ(t−1), according to (3), (4), (5) and (6).
4. CM-step: Given the estimated sufficient statistics, obtain the current estimates of D, α, σ20 and
σ2, using (10), (11) and (12) and (13), respectively.
5. Repeat 3-4 until convergence.
the small amount of sporadic missingness, we treat them as MAR and remove the
corresponding data points from the evaluation of the likelihood function. Specifi-
cally, if a protein is measured in l (l < 4) samples in a 4-plex iTRAQ experiment,
we will set pi = l and apply the proposed method.
3.5. Logit probability functions for BADMM. The probability of missingness
in (2) is designed to characterize the BADMM for abundance data from iTRAQ or
other proteomics experiments. By using an exponential function, the probability of
missingness in (2) can be naturally integrated with the density function of normal
distributions. Thus, closed-form solutions can be obtained in the ECM algorithm,
which makes the computation efficient.
In some instances, for example, when tumor and normal samples are matched
and paired, and each pair is considered as an “observation” in the iTRAQ experi-
ment, there may be a need to analyze log-ratio data (i.e. log of ratios of abundances
of a tumor sample versus the matching normal sample). In this situation, if a feature
has low abundance in either the tumor or the normal sample, the observed log-ratio
values for the pair would be extreme, and the feature would be more likely to
be missing. The exponential function-based BADMM is not suitable to model the
missing-data pattern for log-ratio data. In those cases, we could use a more general
and flexible logistic function for modelling the missing-data mechanism (Little and
Rubin, 2002; Luo et al., 2009):
(16) logit(Pr(Mi = 1|yi)) = γ0 + γ/pi · 1Tyi + γ2 ·Ci,
where Ci is a set of covariates associated with the experiment i (or the i-th batch),
and γ2 is the corresponding coefficient. In our motivating example, we do not have
any experiment-specific (nor batch-specific) covariate, and thus the last term is not
considered.
For the logit missing-data mechanism in (16), we will use numeric integration
(Pinheiro and Bates, 1995) to obtain the conditional means and variances for y(t)i ’s
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in the missing batches, and replace the corresponding terms in (7), (8) and (9) with
the following:
y
(t)
i = E(yi|Mi = 1,Ω(t)) =
∫
yiP (Mi = 1|yi)φ(yi,Xiα(t),Σ(t)i )dyi∫
P (Mi = 1|yi)φ(yi,Xiα(t),Σ(t)i )dyi
,
var(yi|Mi = 1,Ω(t)) = E(yiyTi |Mi = 1,Ω(t))− y(t)i y(t)i
T
;
b
(t)
i = E(bi|yi,Mi = 1,Ω(t)) = D(t)ZTi W(t)i
(
y
(t)
i −Xiα(t)
)
,
var(bi|yi,Mi = 1,Ω(t)) = D(t) −D(t)ZTi W(t)i ZiD(t) +
D(t)ZTi W
(t)
i var(yi|Mi = 1,Ω(t))W(t)i ZiD(t);
and V(t)i = var(ei|yi,Mi = 1,Ω(t)) = ZiD(t)ZTi − ZiD(t)ZTi W(t)i ZiD(t)ZTi
+RiW
(t)
i var(yi|Mi = 1,Ω(t))W(t)i Ri.
4. Simulations.
4.1. Comparison of modelling absolute abundance via mixed-effects models
versus modelling relative abundance. To remove batch-effects in iTRAQ-based
proteomics analyses, a standard practice is to analyze the relative abundance of a
protein/peptide in the target samples relative to the abundance level of the pro-
tein/peptide in the reference sample from the same batch, and assess the asso-
ciation of relative abundance of each protein/peptide with the phenotype. In this
simulation section, we will show that directly modelling absolute abundance with
mixed-effects model-based approaches improve over conventional analysis based
on relative abundances.
We simulated 1,000 multivariate normal data sets yi ∼ N(Xiα + Zibi,R)
with p = 4 for batch size of Q = 40 and Q = 200. The fixed effects are Xiα.
Here Xi is a p × (k + 1) (k = 2) covariate matrix for each observation i with the
first column being 1, and α = (10,−a, a)T . In assessing the type I error rate, we
set a = 0; in evaluating the power, we set a = 0.7 when Q = 40 and a = 0.3
when Q = 200. Here we only included a random intercept for each batch. The
random effect is bi ∼ N(0, D), and Zi is a vector of 1’s. R is a diagonal matrix
with diagonal elements (σ20, σ
2, σ2, σ2). We simulated two scenarios: when the
experimental variation is large, σ20 = 2, σ
2 = 4, D = 3; and we also simulated
a scenario with smaller experimental variation, σ20 = 1, σ
2 = 2, D = 1. Note σ20
represents the variance of the reference sample, which is purely due to experimental
variation across different iTRAQ multiplex; while σ2 represents the variance of
the target samples, which is a combination of both biological and experimental
variation. Thus, the reference sample variance is often smaller than the variance of
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other tumor samples. We generated approximately 40% missing data at the batch-
level by the mechanism in (2) with γ0 = 0 and γ = 0.1 We also generated an
additional 5% sporadic (random) missingness.
When applying the mixEMM method, based on the estimated MLEs for the fixed
effects and their variance estimates in (14), we first obtained the Wald test statis-
tics for testing H0 : α−1 = 0, where α−1 stands for the fixed effects other than
the mean (i.e. the intercept), and then derived the p-values by approximating the
null distribution through permuting the order of batches of response variables. We
compared two versions of the mixEMM method: one with and one without incor-
porating BADMM by setting γ = 0.1 and 0, respectively. Note, when γ = 0, the
missing mechanism is treated as MAR (missing at random).
We also compared the performance of mixEMM with that of the conventional
analysis based on relative abundances: we treated relative abundances as responses
and fitted linear regressions to detect significant associations (regression coeffi-
cients). Again, p-values were derived through permutation tests in the same way as
we did for mixEMM.
Table 1 shows that with permutation-based p-values, all the three methods can
control type I error rates at different p-value thresholds in different scenarios. Com-
paring with the conventional approach of analyzing relative abundance, both ver-
sions of mixEMM enjoyed much improved power. In particular, when experimental
variation is large, the improvement of power could be 3 to 4 folds. These results
clearly demonstrated the advantage of modeling the batch design through a mixed-
effects model, which helps to characterize the variance structure in the data more
precisely. The two versions of mixEMM (γ = 0.1 v.s. γ = 0) enjoys similar power
in all settings. This suggests that BADMM has only limited impacts on the testing
results. However, in the next section, we demonstrated that incorporating BADMM
will improve parameter estimation.
4.2. The BADMM modeling in mixEMM. We simulated 1,000 multivariate nor-
mal data sets similar as before with α = (10,−1, 1)T , σ20 = 2, σ2 = 4. We gen-
erated approximately 40% missing data at the batch-level by the mechanism in (2)
with γ0 = 0 and γ = 0.1, and an additional 5% sporadic (random) missingness.
Table 2 shows the relative Mean Squared Errors (MSEs) of mixEMM incorpo-
rating BADMM (γ = 0.1) versus mixEMM without considering BADMM (γ = 0)
on estimates for the fixed effects and variance with different sample sizes. The rel-
ative MSEs for the fixed effects estimates are approximately 0.8 for Q = 40, and
0.5 for Q = 200. This suggests that by taking into account the missing batches,
the proposed mixEMM method provides more accurate estimates for fixed effects
in both the limited and large sample scenarios. The relative MSEs for variance esti-
mates are very close to 1, indicating that modelling the non-ignorable missingness
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TABLE 1
Type I error rate and power comparison. We compare the type I error rates and power of the
mixEMM method with and without considering BADMM, as well as linear regressions using relative
abundances as responses.
# batch P -value mixEMM mixEMM Linear regression
(experiment) Variance cutoff γ = 0.1 γ = 0 on relative abundance
40
large 0.05 0.055 0.056 0.048
0.01 0.007 0.007 0.014
small 0.05 0.060 0.063 0.047
Type I 0.01 0.012 0.012 0.012
error
200
large 0.05 0.045 0.045 0.058
rate 0.01 0.008 0.008 0.007
small 0.05 0.055 0.057 0.050
0.01 0.008 0.010 0.017
40
large 0.05 0.437 0.442 0.150
0.01 0.267 0.263 0.068
small 0.05 0.959 0.957 0.507
0.01 0.898 0.899 0.240
Power
200
large 0.05 0.491 0.472 0.178
0.01 0.248 0.259 0.065
small 0.05 0.979 0.979 0.555
0.01 0.895 0.901 0.306
imsart-aoas ver. 2011/11/15 file: MixEMM_AOAS_Final.tex date: August 29, 2018
A MIXED-EFFECTS MODEL FOR DATA WITH BATCH-LEVEL NON-IGNORABLE MISSINGNESS15
mainly helps to correct the biases in the fixed effects estimates rather than variance
estimates.
In addition to the simulations above, we also re-analyzed the simulated data
using the logit missing-data mechanism function in (16) and compared the relative
MSEs. Note that the simulated data are generated from the exponential BADMM
in (2), and we use the logit function to analyze the data, with γ0 = 0 and γ =
0.1. That is, the missing-data mechanism is potentially mis-specified. The relative
MSEs based on the logit function are close to those based on the true BADMM,
with only a minor loss of efficiency. Since the logit function is quite flexible and
fits the observed missing-data pattern well, the overall biases of the fixed effects
estimates are quite small. This suggests that the logit BADMM function is a general
and flexible missing-data mechanism function. When data are generated by logit
BADMM and re-analyzed by exponential BADMM, as long as the exponential
pattern nicely fits the observed missing data pattern, the conclusions are similar
(results not shown).
When the two BADMM mechanisms produce similar patterns, the exponential
function is about 15 times faster than the logit function. Specifically, in terms of
computation time, it takes 0.287 and 1.514 hours for a single node computer to
analyze 1,000 features based on the exponential BADMM when sample sizes are
40 and 200, respectively, whereas it takes 4.460 and 24.243 hours for the anal-
ysis based on the logit BADMM. The computation time increases rapidly with
dimensionality p and sample size n. When jointly analyzing multiple features, for
example multiple peptides from iTRAQ data with 8 channels, the superiority of
the exponential BADMM would become more substantial. Additionally, the logit
BADMM would be useful in analyzing log-ratio data or when exponential pattern
does not fit well.
The fit of the selected and estimated BADMM pattern should often be checked
before using the mixEMM method in the estimation and inference. For example, in
our real data application, we evaluate the fit of the exponential BADMM in Figure 2
before the subsequent analysis.
4.3. Evaluating available-case-based missing-data mechanism parameter es-
timates. In the simulations above when applying the mixEMM, we either used
the true missing-data mechanism with true parameters, or we use a mis-specified
mechanism with mis-specified parameters. In this subsection, we evaluated the es-
timation of the missing-data mechanism parameter. Specifically, we pooled all fea-
tures together and obtained the available-case mean abundance estimates and the
proportion of missing batch for each feature. We estimated the missing-data mech-
anism parameter based on (15) for the exponential BADMM in (2) given the data.
We simulated 1,000 features with means randomly sampled from N(10, 22),
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TABLE 2
The comparison of relative MSEs and computation time for estimates of fixed effects and variance
components obtained from incorporating BADMM (γ = 0.1) relative to those assuming MAR
(γ = 0) in mixEMM. The missing data are generated according to the exponential BADMM in (2).
We compare the relative MSEs when the true missing-data mechanism is accounted in the estimation
of the mixEMM algorithm, and when the logit BADMM is used in the estimation with estimated
missing-data mechanism parameters. The results are based on 1,000 repeated simulations.
Computation
Methods # experiment α σ20 σ2 D time
Q (in hours)
mixEMM with 40 0.848 1.014 1.006 1.184 0.287
exponential BADMM 200 0.492 1.016 1.006 1.015 1.514
mixEMM with 40 0.851 1.004 1.002 1.047 4.460
logit BADMM 200 0.538 1.007 1.004 0.983 24.243
other parameters similar to those in previous sections, and the number of batches
Q = 40 and Q = 200. We generated batch-level missingness by (2) with γ0 = 0
and γ = 0.1 and calculated γˆ0 and γˆ based on the 1,000 features. We repeated
the procedure 100 times, and Table 3 lists the distribution of γˆ0 and γˆ. Although
available-case based mean estimates of feature abundances could have substantial
biases, the estimates for γ are reasonably accurate. We note that estimates for γ0
based on available-case means can be biased. However, since γ0 does not affect the
E- nor the CM-step, the overall performance of available-case-based missing-data
mechanism parameters is almost identical to that of using true parameters.
5. Application to the CPTAC proteomics data to identify proteins related
to triple negative breast cancer tumors. Triple negative breast cancer (TNBC)
refers to breast cancer that does not express the genes for estrogen receptor, pro-
gesterone receptor or Her2/neu. TNBC patients have a much higher risk of relapse
for the first 35 years compared to other types of breast cancer patients. It is also
more difficult to treat TNBC since most chemotherapies target one of the three re-
ceptors. There is a pressing need to develop more effective treatment strategies for
TNBC patients. In this section, we applied the proposed mixEMM algorithm to the
motivating proteomics dataset from the CPTAC breast cancer project (Paulovich
et al., 2010; Ellis et al., 2013), with the goal of identifying phosphopeptides up or
down regulated in TNBC tumors compared to other types of breast cancer tumors.
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TABLE 3
The distribution of available-case-based estimated missing-data mechanism parameters based on
100 repeated simulations.
# batch parameter true value min median mean max
40
γ 0.1 0.093 0.101 0.101 0.107
γ0 0 -0.119 -0.059 - 0.055 0.029
200
γ 0.1 0.097 0.104 0.104 0.108
γ0 0 -0.134 -0.094 -0.093 -0.014
Such information can help to shed light on the disease mechanism of TNBC, which
then may lead to better clinical practice for TNBC diagnosis and treatment.
In the CPTAC breast cancer project, a total of 108 tumor samples from 105
breast cancer patients were analyzed in 36 four-plex iTRAQ experiments gener-
ated at Dr. Carr’s lab at the Broad Institute of MIT and Harvard, Boston, US. Each
iTRAQ experiment processed 3 breast tumor samples and the reference sample,
which was created by combining 40 of these tumors. The iTRAQ-labeled peptides
were fractionated and chemically enriched for phosphopeptides. The resulting sam-
ples were processed using high resolution MS instruments (LS-MS/MS on Thermo
Q-Exactive). Phosphopeptide identification and quantification were performed us-
ing Spectrum Mill software (Agilent Technologies, Santa Clara, CA).
In this application, we focus on phospho-proteomics data and will analyze each
individual phosphopeptide. Missing data problem in phospho-proteomics data is
usually quite severe, and thus raises a pressing need for statistical methods properly
incorporating the non-ignorable missingness. In total, there were 61,698 phospho-
peptides being identified and quantified in at least one sample. However, only 4,415
(7.2%) phosphopeptides had complete measurements in all the samples. The miss-
ing rates of each sample ranged from 58.21% to 83.40%. Among all missing obser-
vations, 99.3% were batch-level missingness, i.e. a phosphopeptide was missing in
all four channels of an iTRAQ experiment. Thus the BADMM pattern suits these
data sets well.
We filtered out the low quality observations, and focused on the 25,961 phos-
phopeptides that were observed in at least 25 (70%) of the 36 runs of the reference
sample. The missing rates of each sample for these 25,961 phosphopeptides ranged
from 3.98% to 48.44% , with a mean value of 10.45%. Figure 2 illustrates the re-
lationships between missing percentage and observed mean abundances of each
phosphopeptide (i.e. 1Tyi in equation (2)). The exponential probabilistic model in
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equation (2) accurately reflects the BADMM pattern in the data.
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Fig 2: An illustration of BADMM based on CPTAC breast cancer phosphopro-
teomics data. (a) A smoothed color density representation of the scatter plot of
the log percentage of missing batches for each phosphopeptide (y-axis) versus its
estimated mean abundances based on the observed data (x-axis). This plot is gen-
erated using R function smoothScatter. The darker the color is, the higher
the density is. The red triangular points indicate medians of mean-abundances of
phosphopeptides with the same missing percentage. The black line represents the
linear regression fit of the red triangular points. (b) Similar plot as (a) except that
the y-axis is on the original scale. The black curve corresponds to the black line in
(a).
We applied the proposed mixEMM method to identify the phosphopeptides up-
or down-regulated in TNBC tumors. In the mixed-effects model, we included a
random effect for each iTRAQ multiplex experiment, and three fixed effects: an
intercept, an indicator for the reference channel, and an indicator for triple nega-
tive subtype. We also conducted the analysis using linear regression models based
on relative abundances for comparison. The resulting p-values of all 25,961 phos-
phopeptides from both methods are illustrated in Figure 3. At Bonferroni adjusted
p-value threshold of 0.05, the mixEMM algorithm considering BADMM identifies
44 phosphosites, corresponding to 29 unique genes, as being significantly up or
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down-regulated in TNBC. Only 3 of these 44 phosphosites have complete obser-
vations in all 108 samples. Nine and three of the 44 phosphosites have a missing
rate great than 30% and 40% respectively. In contrast, the conventional analysis
based on relative abundances failed to detect any significant phosphosite at the
same significance threshold. These results are consistent with what we observed
in the simulated data examples, and the mixEMM method enjoys improved power
over conventional methods.
The phosphosite with the most significant p-value corresponds to the gene FOXA1,
a transcription factor. The gene FOXA1 is known to be associated with breast can-
cer risk (Meyer and JS, 2012). A more recent work further suggests that FOXA1
silencing increases migration and invasion of breast cancer cells (Bernardo et al.,
2013). This is consistent with our finding that phosphoprotein of FOXA1 was sig-
nificantly down-regulated in TNBC tumors, and TNBC tumors are usually more
aggressive than other subtypes of breast cancer. Moreover, according to the STRING
data base (Szklarczyk et al., 2014), FOXA1 interacts with another gene SOX10 —
in the significant 29 gene list. The gene SOX10 is a neural crest transcription factor.
It was reported to be preferentially expressed in TNBC based on a recent immuno-
histochemistry study (Cimino-Mathews et al., 2013), and was also validated as a
sensitive diagnostic marker for basal-like TNBC (Ivanov et al., 2013). The pro-
posed mixEMM method detects these known TNBC genes and that strengthens our
confidence that the mixEMM method will help to reveal biological relevant infor-
mation underlying iTRAQ data. Further investigation on how FOXA1, SOX10 and
the other 27 significant genes function may help us better understand the disease
mechanism and improve the development of novel diagnostic and therapeutic tools
for TNBC.
6. Discussion. In this paper, we propose a new method — mixEMM — for an-
alyzing data from iTRAQ proteomics experiments. The proposed mixEMM method
employs a mixed-effects model to characterize the variance structure for the abun-
dance measurements from iTRAQ experiments. It uses an exponential probability
function to model the batch-level non-ignorable missing-data mechanism (BADMM)
in the iTRAQ data. The goal of our analyses is to estimate the fixed effects for the
association between proteomic features and sample phenotypes (e.g. clinical out-
comes). To achieve this goal, we implement an ECM algorithm to calculate the
MLEs of the parameters of interest. The superior performance of the mixEMM
method over the conventional analysis approach is illustrated using both simula-
tions and a real data example.
In practice, the experimental variation across different iTRAQ experiments is of-
ten not small. In other words, even for the same reference sample, its protein/peptide
abundance measurements in different batches measured by different iTRAQ exper-
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Fig 3: The relationship between p-values and missing rates. (a) The results from
mixEMM-based analysis using absolute abundances and considering BADMM; (b)
the results from linear regression analysis using relative abundances. In both (a)
and (b), X-axis represents the missing rates of phosphosites and Y-axis represents
the negative log10 of p-values. Phosphopeptides are colored in red if their p-values
are below the Bonferroni corrected p-value cutoff (0.05/25961), and are colored
in blue otherwise.
iments may differ substantially. The conventional approach directly analyzes rel-
ative abundance measures, which in some sense mix up the variation in the target
samples and the reference samples, and consequently causes a loss of efficiency
and power. In contrast, mixEMM precisely characterizes the experimental proper-
ties, accounts for the variation of reference sample across batches, and gain sub-
stantial power improvement in the subsequent tests.
While explicitly modeling BADMM has limited impact on testing, it can im-
prove parameter estimations for fixed effects. In addition to the exponential proba-
bility function for BADMM, we also investigate the use of logit functions for mod-
elling the missing-data mechanism. When both functions fit the observed missing-
data pattern well, the estimation accuracies of the two functions are comparable,
and the computationally efficient exponential function is recommended. The logit
BADMM function is more flexible and can be used in the analyses of log-ratio
data or data with more complex missing data patterns. Other flexible missing-data
mechanism functions such as spline functions can be incorporated into the pro-
posed framework, although numerical integration would be required.
This work was motivated by phosphoproteomics data, in which the natural anal-
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ysis unit is each individual phosphopeptide and each phosphopeptide is directly
quantified in the experiments. For global proteomics data, the quantification is ob-
tained at the peptide level while the target analysis unit is each individual protein.
In order to perform inference at the protein level, one strategy is to apply the pro-
posed mixEMM algorithm at the peptide level data and then summarize the results
of peptides within each protein. Another strategy is to first calculate protein abun-
dances based on the mean or median of peptide abundances within each protein
and then apply the proposed mixEMM method to the summary protein abundances.
A more sophisticated treatment would be to perform a multivariate analysis and
jointly model multiple peptides of the same protein. Research along this direction
is on-going.
The proposed framework is not limited to proteomics data analysis, and is gen-
erally applicable to data with repeated/clustered measures and cluster-level incom-
plete data. An R package mixEMM will be available through CRAN.
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